Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
featured
A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma

A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma

lymphoid malignancy
idelalisib
refractory follicular lymphoma
  • 307 views
  • 23 Nov, 2020
  • 6 locations
Dose Optimization Study of Idelalisib in Follicular Lymphoma

The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other

lymphoid malignancy
cancer
rituximab
refractory follicular lymphoma
ct scan
  • 0 views
  • 03 Sep, 2021
  • 186 locations
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL

to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.

rituximab
neutrophil count
chronic lymphocytic leukemia
btk inhibitor
idelalisib
  • 2 views
  • 23 Sep, 2021
  • 111 locations
Rituximab Idelalisib and Venetoclax in Relapsed/Refractory CLL/SLL

To determine the recommended phase 2 dose (RP2D) of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory Chronic lymphocytic leukemia/ Small

neutrophil count
chronic lymphocytic leukemia
fludarabine
ibrutinib
stem cell transplantation
  • 0 views
  • 26 Jan, 2021
  • 1 location
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.

  • 0 views
  • 08 Aug, 2021
  • 2 locations
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

ensure clinical benefit and to minimize the occurrence of early overlapping toxicity with pembrolizumab as most toxicities were observed early on in the treatment with idelalisib, a related PI3K

rituximab
pembrolizumab
measurable disease
neutrophil count
idelalisib
  • 78 views
  • 28 Jan, 2021
  • 3 locations
Assessment of the Quality of Life of Patients With Lymphomas Treated With Oral Therapy

receive oral therapy at home. Ibrutinib, acalabrutinib, idelalisib, venetoclax and lenalidomide are oral therapies used in the treatment of Chronic Lymphoid Leukemia, Follicular Lymphoma, Waldenstrm's

  • 0 views
  • 11 Aug, 2021
  • 1 location